Information

Related Research Units

Molecular Medicine Research

Publications

  1. Effect of the S2' site cleavage on SARS-CoV-2 spike. Nat Commun. 2025 Nov 27. View Abstract
  2. Specific Interactions between HIV-1 Env Cytoplasmic Tail and Gag Matrix Domain Probed by NMR. J Am Chem Soc. 2025 May 28; 147(21):17561-17565. View Abstract
  3. SARS-CoV-2 spike protein: structure, viral entry and variants. Nat Rev Microbiol. 2025 May 06. View Abstract
  4. Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole. J Clin Oncol. 2024 Aug 20; 42(24):2887-2898. View Abstract
  5. Antibody-mediated SARS-CoV-2 entry in cultured cells. EMBO Rep. 2023 Dec 06; 24(12):e57724. View Abstract
  6. Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer. J Clin Oncol. 2023 Dec 10; 41(35):5356-5362. View Abstract
  7. Structural and functional characteristics of the SARS-CoV-2 Omicron subvariant BA.2 spike protein. Nat Struct Mol Biol. 2023 07; 30(7):980-990. View Abstract
  8. Cryo-EM structure of SARS-CoV-2 postfusion spike in membrane. Nature. 2023 Jul; 619(7969):403-409. View Abstract
  9. Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32). Breast Cancer Res Treat. 2023 Jul; 200(1):93-102. View Abstract
  10. Distinct in vitro and in vivo neutralization profiles of monoclonal antibodies elicited by the receptor binding domain of the ancestral SARS-CoV-2. J Med Virol. 2023 03; 95(3):e28673. View Abstract
  11. An antibody from single human VH-rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion. Sci Immunol. 2022 10 28; 7(76):eadd5446. View Abstract
  12. Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. JAMA. 2022 05 24; 327(20):1963-1973. View Abstract
  13. Structural and functional impact by SARS-CoV-2 Omicron spike mutations. Cell Rep. 2022 04 26; 39(4):110729. View Abstract
  14. Fighting SARS-CoV-2 with structural biology methods. Nat Methods. 2022 04; 19(4):381-383. View Abstract
  15. Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. Science. 2021 Dec 10; 374(6573):1353-1360. View Abstract
  16. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022 01; 23(1):3-20. View Abstract
  17. Structure of SARS-CoV-2 spike protein. Curr Opin Virol. 2021 10; 50:173-182. View Abstract
  18. Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. JNCI Cancer Spectr. 2021 10; 5(5). View Abstract
  19. Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. Science. 2021 08 06; 373(6555):642-648. View Abstract
  20. Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. NPJ Breast Cancer. 2021 Jun 08; 7(1):74. View Abstract
  21. Structural impact on SARS-CoV-2 spike protein by D614G substitution. Science. 2021 04 30; 372(6541):525-530. View Abstract
  22. The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. J Natl Cancer Inst. 2021 02 01; 113(2):192-198. View Abstract
  23. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. Nat Struct Mol Biol. 2021 02; 28(2):202-209. View Abstract
  24. Distinct conformational states of SARS-CoV-2 spike protein. Science. 2020 09 25; 369(6511):1586-1592. View Abstract
  25. Structural basis of transmembrane coupling of the HIV-1 envelope glycoprotein. Nat Commun. 2020 05 08; 11(1):2317. View Abstract
  26. HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes. Nat Chem Biol. 2020 05; 16(5):529-537. View Abstract
  27. Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor a. Clin Cancer Res. 2020 06 15; 26(12):2986-2996. View Abstract
  28. Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer. Pharmacogenet Genomics. 2019 10; 29(8):183-191. View Abstract
  29. Molecular Mechanism of HIV-1 Entry. Trends Microbiol. 2019 10; 27(10):878-891. View Abstract
  30. Structural basis of coreceptor recognition by HIV-1 envelope spike. Nature. 2019 01; 565(7739):318-323. View Abstract
  31. Structure of the membrane proximal external region of HIV-1 envelope glycoprotein. Proc Natl Acad Sci U S A. 2018 09 18; 115(38):E8892-E8899. View Abstract
  32. Conformational States of a Soluble, Uncleaved HIV-1 Envelope Trimer. J Virol. 2017 05 15; 91(10). View Abstract
  33. Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. Breast Cancer Res Treat. 2017 Jul; 164(2):371-378. View Abstract
  34. Antigenicity-defined conformations of an extremely neutralization-resistant HIV-1 envelope spike. Proc Natl Acad Sci U S A. 2017 04 25; 114(17):4477-4482. View Abstract
  35. Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. Cancer Res. 2016 12 01; 76(23):7012-7023. View Abstract
  36. Structural basis for membrane anchoring of HIV-1 envelope spike. Science. 2016 Jul 08; 353(6295):172-175. View Abstract
  37. HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein. Science. 2015 Jul 10; 349(6244):191-5. View Abstract
  38. Stable, uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded trimer with a native-like structure. Proc Natl Acad Sci U S A. 2014 Dec 30; 111(52):18542-7. View Abstract
  39. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J Virol. 2014 Jan; 88(2):1249-58. View Abstract
  40. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci U S A. 2012 Jul 24; 109(30):12111-6. View Abstract
  41. Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody. Structure. 2010 Dec 08; 18(12):1632-41. View Abstract
  42. Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nat Struct Mol Biol. 2010 Dec; 17(12):1486-91. View Abstract
  43. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A. 2009 Dec 01; 106(48):20234-9. View Abstract
  44. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci U S A. 2008 Mar 11; 105(10):3739-44. View Abstract
  45. Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis. 2008 Mar; 29(3):568-72. View Abstract
  46. Restraining the conformation of HIV-1 gp120 by removing a flexible loop. EMBO J. 2006 Oct 18; 25(20):5026-35. View Abstract
  47. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature. 2005 Feb 24; 433(7028):834-41. View Abstract
  48. Determining the structure of an unliganded and fully glycosylated SIV gp120 envelope glycoprotein. Structure. 2005 Feb; 13(2):197-211. View Abstract
  49. A chimeric protein of simian immunodeficiency virus envelope glycoprotein gp140 and Escherichia coli aspartate transcarbamoylase. J Virol. 2004 May; 78(9):4508-16. View Abstract
  50. Expression, purification, and characterization of gp160e, the soluble, trimeric ectodomain of the simian immunodeficiency virus envelope glycoprotein, gp160. J Biol Chem. 2000 Nov 10; 275(45):34946-53. View Abstract
  51. De novo and DNA primer-mediated initiation of cDNA synthesis by the mauriceville retroplasmid reverse transcriptase involve recognition of a 3' CCA sequence. J Mol Biol. 1997 Aug 22; 271(3):311-32. View Abstract
  52. Cloning and characterization of the Neurospora crassa cyt-5 gene. A nuclear-coded mitochondrial RNA polymerase with a polyglutamine repeat. J Biol Chem. 1996 Mar 15; 271(11):6537-44. View Abstract

Contact Bing Chen

Phone: 617-355-4625
Print Profile